Advertisement
News
Subscribe to MDT Magazine News

Exergen TemporalScanner Sponsors 'Game Time Temperature' for NFL and College Bowl Games

January 10, 2011 7:36 am | by Bio-Medicine.Org | Comments

WATERTOWN, Mass., Jan. 10, 2011 /- Drawing attention to its TemporalScanner™ Temporal Artery Thermometer during flu season, Exergen® Corporation is sponsoring "game-time temperature" for national radio broadcasts of NFL games and the upcoming College Bowl football games. The...

TOPICS:

MedAvante Names Leading Expert to Head Neurocognition Therapeutic Area

January 10, 2011 7:35 am | by Bio-Medicine.Org | Comments

HAMILTON, N.J., Jan. 10, 2011 /- MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system (CNS) disorders, announced the appointment of Christopher Randolph, PhD, ABPP-CN, to the new position of Vice President, Neurocognition.  Dr....

TOPICS:

Gilead Sciences extends study of HIV drug

January 10, 2011 6:45 am | by The Associated Press | Comments

Gilead Sciences Inc. said Monday that, at the recommendation of the Food and Drug Administration, it will double the length of its late-stage study of HIV drug candidate elvitegravir to almost two years.Gilead said the study, which compares elvitegravir to Merck & Co.'s drug Isentress, will now...

Advertisement

Mindray estimates 2010 profit grew 10 percent

January 10, 2011 6:45 am | by The Associated Press | Comments

Mindray Medical International Ltd. said Monday it estimates that its adjusted profit in 2010 grew about 10 percent greater than its profit in 2009.The Shenzhen, China, company also said it estimates its revenue grew about 10 percent. In 2009, Mindray reported a profit of $147.4 million, or...

Ceapro Announces Debt Reduction

January 10, 2011 4:45 am | by The Associated Press | Comments

Ceapro Inc. (TSX VENTURE: CZO) today announced that pursuant to a debt settlement agreement made with the members of its board of directors previously announced on December 13, 2010, it has issued 1,590,909 common shares in full satisfaction of debts totaling $175,000. The shares issues...

Kinetic Concepts buys TechniMotion Medical

January 10, 2011 4:45 am | by The Associated Press | Comments

Medical technology company Kinetic Concepts Inc. said Monday it acquired TechniMotion Medical, which develops patient handling systems for acute and post-acute care. Terms of the deal were not disclosed.Kinetic, which is based in San Antonio, said TechniMotion products include lifts for...

Ziptronix accuses TSMC / Omnivision of Patent Infringement Over Oxide Bonding Technology

January 10, 2011 4:38 am | by I-Micronews | Comments

In December 2010 Ziptronix filed a complaint against TSMC and Omnivision in US District Court alleging ?willful and deliberate? infringement of several Ziptronix patents pertaining to low temperature oxide bonding.

Civitas spins out Alkermes' inhaled drug tech with $20M financing

January 10, 2011 4:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Civitas Therapeutics Inc. has launched in Chelsea with $20 million in Series A funding, spun out of the inhaled drug delivery program at Alkermes Inc.. The new company will use the manufacturing facility in Chelsea that was idled when Eli Lilly pulled out of a deal with Alkermes in 2008.

Advertisement

New pharmaceuticals startup Dekkun raises $10M

January 10, 2011 4:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Stealthy, early-stage pharmaceuticals company Dekkun Corp. has raised $9.93 million of a planned $30.5 million equity offering, according to a regulatory filing. The startup operates out of the office of HealthCare Ventures LLC, a life sciences-focused venture capital firm.

New Langer startup to develop oral insulin

January 10, 2011 4:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Prolific MIT life sciences inventor Robert Langer is behind a new startup, called Entrega Inc., backed by Boston-based drug developer Enlight BioSciences and focused on oral drug delivery technology for biologic drugs.

Cardinal Health to Release Second-Quarter Results on Feb. 3

January 10, 2011 4:36 am | by Bio-Medicine.Org | Comments

DUBLIN, Ohio, Jan. 10, 2011 /- Cardinal Health plans to release second-quarter financial results for its fiscal 2011 on Thursday, Feb. 3, prior to the opening of trading on the New York Stock Exchange. The company has scheduled a webcast and conference call for Feb. 3 at 8:30 a.m. EST to...

TOPICS:

CoreLab Partners Launches Advanced Imaging Application

January 10, 2011 4:36 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., Jan. 10, 2011 /- CoreLab Partners, Inc , the global entity resulting from the merger between RadPharm, Inc and Medifacts International, has launched a new advanced imaging application named ImagEngine® . "We are pleased to announce the release of our proprietary...

TOPICS:

Shionogi Inc. Announces Commercial Availability of KAPVAYâ„¢ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD

January 10, 2011 4:36 am | by Bio-Medicine.Org | Comments

FLORHAM PARK, N.J., Jan. 10, 2011 /- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral...

TOPICS:

Genetics Squared Changes Name To Everist Genomics

January 10, 2011 4:35 am | by Bio-Medicine.Org | Comments

ANN ARBOR, Mich., Jan. 10, 2011 /- Genetics Squared, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced that it will change its corporate name to Everist Genomics and has appointed Prasad Sunkara, Ph.D. as its...

TOPICS:

Safety and Efficacy of OrbusNeich's Genousâ„¢ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy

January 10, 2011 4:35 am | by Bio-Medicine.Org | Comments

HONG KONG, Jan. 10, 2011 /- Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents (DES) and the accompanying requirement of long-term dual antiplatelet therapy (DAPT) showed positive safety and short- and...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading